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Background: Hereditary angioedema (HAE) is characterized by unpredictable attacks of debilitating subcutaneous
and mucosal edema. Gastrointestinal attacks are painful, of sudden onset and often mistaken for acute abdomen
leading to unnecessary surgery. The purpose of this study was to analyze symptom presentation of gastrointestinal
angioedema in pediatric and adult HAE patients.
Methods: Information collected during the clinical development of ecallantide for treatment of acute HAE attacks
included affected anatomic location, accompanying symptoms, medical history, and pain assessments. Efficacy
endpoints included Treatment Outcome Score (TOS, maximum score = 100; minimally important difference = 30), a
point-in-time measure of treatment response, and time to treatment response.
Results: Forty-nine percent of 521 HAE attacks only involved abdominal symptoms. The most commonly reported
abdominal symptoms were distension (77%), cramping (73%) and nausea (67%). The most common pain
descriptors were tender, tiring-exhausting, aching, cramping and sickening. White blood cell counts were elevated
(>10 × 109/L) in 23% of attacks (mean ± SD: 15.1 ± 11.27 × 109/L). A high proportion of patients reported a history
of abdominal surgery, including appendectomy (23%), cholecystectomy (16.4%), and hysterectomy (8.2%). Mean
TOS at 4 hours post ecallantide was 77±33 versus 29±65 for placebo. Median time to significant symptom resolution
was 165 minutes (95% CI 136, 167) for ecallantide versus >4 hours (95% CI 161, >4 hours) for placebo. Anaphylactic
reactions occurred in 6 of the 149 treated patients.
Conclusions: HAE should be considered in the differential diagnosis of patients with recurrent discrete episodes of
severe, unexplained crampy abdominal pain associated with nausea.
Trials registration: The data used in the analysis were gathered across multiple clinical trials conducted during the
clinical development program for ecallantide. All of the studies were conducted using Good Clinical Practices (GCP)
and in accordance with the ethical principles that have their origins in the Declaration of Helsinki. Each site that
participated in the clinical trials obtained the appropriate IRB or Ethics Committee approval prior to enrolling any
patients. All patients provided written informed consent prior to undergoing any study-related procedures. Pediatric
patients provided written assent and their parents or guardians gave written informed consent.
The following trials have been registered at www.clinicaltrials.gov: EDEMA2 (identifier NCT01826916); EDEMA3
(identifier NCT00262080); EDEMA4 (identifier NCT00457015); and DX-88/19 (identifier NCT00456508).
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Hereditary angioedema (HAE) is a rare and potentially
life-threatening disease. It is characterized by non-pitting,
non-pruritic swelling of subcutaneous or submucosal tis-
sues of the skin, extremities, genitalia, respiratory and/or
gastrointestinal tracts [1]. Because of the rarity of the dis-
ease and its self-resolving nature, many patients have his-
torically faced a prolonged time to diagnosis (>10 years)
[2]. The disease has an autosomal dominant pattern of in-
heritance and therefore patients typically present with a
family history of angioedema. However, ~25% of cases are
due to de novo mutations such that a family history is not
always present [3]. Abdominal HAE attacks are very com-
mon, with up to 87% of patients rating abdominal attacks
as excruciating or severely painful [4] often causing the
patient to seek medical attention. Symptoms of abdominal
HAE attacks often mimic other diseases such as appendi-
citis, small bowel obstruction, inflammatory bowel disease,
gall bladder disease or diverticulitis. As a result, many pa-
tients report undergoing unnecessary abdominal surgery
prior to diagnosis [5]. Thus, abdominal HAE attacks
contribute significantly to the reduced quality of life and
economic burden of HAE patients. Moreover, the accur-
ate diagnosis of the disease, especially in patients who
present only with recurrent abdominal symptoms, re-
mains a challenge.
The primary cause of HAE is a deficiency in C1-
inhibitor (HAE-C1INH), although HAE with normal
C1-INH (HAEnC1) has been described [6]. C1-INH is a
serine-protease inhibitor that regulates the activation of
the coagulation, kallikrein-kinin and complement systems,
with the kallikrein-kinin system playing a central role in
the pathophysiology of HAE-C1INH [7]. During an HAE-
C1INH attack, deficiency in C1-INH results in the un-
regulated activation of plasma kallikrein, a protease which
cleaves high molecular weight kininogen to form the potent
vasodilator bradykinin. As a result, excessive bradykinin
is produced and activates the bradykinin B2 receptor on
endothelial cells, causing the edema and inflammation char-
acteristic of an HAE attack [7]. The precipitating events for
an HAE attack are unknown but stress and minor trauma
are thought to contribute.
The reported manifestations of intestinal angioedema
in the literature include abdominal pain with or with-
out nausea, vomiting and diarrhea, and abdominal dis-
tension from ascites [4,8]. These symptoms are due to
edema of the bowel wall which can lead to partial or
complete small bowel obstruction often with associated
ascites [8,9]. Prior abdominal surgeries further compli-
cate abdominal attacks due to the possibility of adhe-
sions causing small bowel obstruction. To date, there
have been limited prospective reports specifically detailing
and quantitating the presenting symptoms of abdominal
HAE attacks.Herein, we provide prospectively collected data from
adult and pediatric HAE-C1INH patients presenting with
abdominal symptoms in the clinical program for ecallan-
tide. Ecallantide is a subcutaneously administered plasma
kallikrein inhibitor that was FDA approved in 2009 for the
treatment of acute attacks of HAE in patients 16 years of
age and older. These data provide information that should
prove useful to the Gastroenterologist, Surgeon and ED
Physician to consider HAE-C1INH when patients report
with recurrent, unexplained abdominal distension, crampy
abdominal pain with nausea.
Methods
Patient population
The analyses presented were generated from data col-
lected in EDEMA0, EDEMA1®, EDEMA2®, EDEMA3®-DB,
EDEMA3®-RD, EDEMA4® and DX-88/19 from patients
with an HAE attack with any abdominal symptoms. All of
the studies were conducted using Good Clinical Practices
(GCP) and in accordance with the ethical principles that
have their origins in the Declaration of Helsinki. Each site
that participated in the clinical trials obtained the appro-
priate IRB or Ethics Committee approval prior to enrolling
any patients (see Additional file 1 for list of IRB/IECs).
All patients provided written informed consent prior to
undergoing any study-related procedures. Pediatric patients
provided written assent and their parents or guardians gave
written informed consent.
Not all studies collected all of the same endpoints and
therefore some of the analyses are based on different pa-
tient populations due to data availability. Eligible patients
were 10 years of age or older (except in EDEMA0 in
which patients were 18 years of age or older), with a diag-
nosis of Type I or Type II HAE. Patients had to report
to the treatment center within 8 hours of an acute HAE
attack that was moderate to severe in intensity. In DX-88/
19 only, patients experiencing mild symptoms were also
eligible for treatment at any time after the development of
symptoms. Table 1 provides a summary of the endpoints
collected in each study, along with the sample size (number
of patients and attacks) analyzed.
Treatments administered
In the EDEMA0, EDEMA1 and EDEMA2 trials, ecallan-
tide was administered intravenously. During the final
Phase II trial (EDEMA2), subcutaneous (SC) administra-
tion of 30 mg ecallantide was introduced and was used
in all subsequent trials. Data describing the baseline at-
tack characteristics (symptoms accompanying abdominal
attacks, attack location, surgical history, white blood cell
[WBC] count, McGill-Short Form [SF] Descriptor Sever-
ity Score) were generated from either IV treated patients
alone or were pooled from both SC and IV treated pa-
tients, including some placebo-treated patients (as these
Table 1 Data collected in EDEMA studies used for abdominal attacks analysis
EDEMA0 EDEMA1 EDEMA2 EDEMA3 EDEMA4 DX-88/19 Patients Attacks
(N) (N)
Symptoms at baseline X X X1 112 296
Attack location X2 X X X 149 521
McGill-SF pain questionnaire
Pain descriptors X X X1 X 242 502
Treatment outcomes X2 X 111 386
VAS for pain X2 X 111 386
Treatment outcome score X2 X X X 149 521
Time to response X X X 149 521
WBC count and surgical history X X X1 X X X 183 569
Abbreviations: SF short form, VAS visual analog scale, WBCwhite blood cell.
1Includes all patients treated in EDEMA2.
2Only includes patients treated in the 30 mg subcutaneous ecallantide treatment arm.
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ministration has no bearing on the baseline attack charac-
teristics). The data on the clinical response to ecallantide
were generated only from those patients treated with SC
ecallantide (the FDA-approved formulation).
Abdominal attack characteristics
Symptoms at baseline and attack location
Baseline symptoms accompanying abdominal attacks were
collected in 3 studies: EDEMA0, EDEMA1 and EDEMA2.
In the SC arm of EDEMA2, as well as EDEMA3, EDEMA4
and DX-88/19 patients identified the location of their
symptoms based on 5 symptom complexes: oropharyn-
geal head/neck (internal head/neck), gastrointestinal (GI)/
abdominal, genital/buttocks, non-oropharyngeal head/neck
(external head/neck), and cutaneous.
Short form McGill pain questionnaire
The McGill Pain Questionnaire (SF-MPQ) consists of 15
pain descriptors (11 sensory; 4 affective) which are rated
on an intensity scale as 0 = none, 1 =mild, 2 =moderate
or 3 = severe [10]. The pain descriptors are aggregated
to calculate the sensory dimension score (includes the
following pain descriptors: throbbing, shooting, stab-
bing, sharp, cramping, gnawing, hot-burning, aching,
heavy, tender, and splitting) and the affective dimension
score (includes the following descriptors: tiring-exhausting,
sickening, fearful, cruel-punishing). Patients experiencing
abdominal attacks were asked to complete the SF-MPQ at
baseline and 4 hours post-treatment to better characterize
the type of pain experienced during abdominal HAE at-
tacks. The pain descriptor analysis includes data from 4
studies (EDEMA0, EDEMA1, EDEMA2 and DX-88/19)
and includes all attacks with any abdominal symptoms.
Descriptor severity scores were calculated by adding up
the total score for all descriptors and dividing by numberof attacks (N = 502). Data from the SC arm of EDEMA2
and DX-88/19 were used for calculating the treatment
outcome in the sensory and affective dimension scores.
VAS pain
Patients who presented with HAE attacks with abdominal
symptoms assessed their own perceptions of pain using a
visual analog scale (VAS). Data from the SC arm of
EDEMA2 and DX-88/19 were used for the VAS analysis.
Patients were instructed to place a slash across a 100 mm
long line at the position that best described their pain, with
possible values ranging from 0 (no pain) to 100 (worst
possible pain). Scoring took place at baseline and at 4 hours
post-treatment.
Efficacy assessments
Treatment outcome score (TOS)
Treatment outcome score (TOS) is a composite measure
of symptom response to treatment. For each individual
symptom complex, patients assess their change in symp-
tom severity using a categorical scale weighted by the
baseline symptom complex severity (significant improve-
ment = 100, improvement = 50, same = 0, worsening = −50,
significant worsening = −100) at 1, 2, 3, 4 and 24 hours
post-treatment. Weighted scores across all sites are aver-
aged to calculate TOS. A TOS value > 0 reflects improve-
ment and the minimally important difference for the TOS
was estimated to be 30.0 [11].
Time to response
To measure overall response to ecallantide or placebo,
patients were asked to compare how they were feeling
following treatment to how they were feeling before treat-
ment. Patients were assessed every 15 min for the first
2 hours, every 30 min for hours 2 – 4, and then at 24 hours.
Response measurements were made using a 5-category
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better”, “unchanged”, “a little worse” or “a lot worse”. Be-
ginning of improvement was the first time within 4 hours
the patient reported feeling “better” (i.e. either “a little bet-
ter or a lot better or resolved”). The time to significant im-
provement was the first time within 4 hours the patient
reported feeling “a lot better or resolved”.
Safety assessments
Safety assessments included the collection of adverse
events (AE) through final follow-up. An AE was defined
as any untoward medical occurrence in a patient that re-
ceived treatment that did not necessarily have a causal
relationship with the treatment.
Results
Abdominal attack presentation
The individual symptoms associated with abdominal at-
tacks at baseline were collected from patients in EDEMA0,
EDEMA1 and EDEMA2. Table 2 provides a summary of
these symptoms. The dataset includes 112 HAE patients
treated for 296 HAE attacks; 154 of these attacks involved
abdominal symptoms. The primary symptoms at baseline
for attacks with abdominal symptoms (N= 154) were dis-
tension (77%), cramping (73%) and nausea (67%). Of note,
diarrhea (14%) and vomiting (21%) were not predominant
symptoms.
Of all attacks with any abdominal pain (N = 521), 49%
presented with isolated abdominal pain only and 33% pre-
sented with abdominal pain and symptoms at another lo-
cation (Figure 1).
Characteristics of abdominal pain in HAE patients
The character and severity of the pain associated with
abdominal symptoms was captured using the SF-MPQ
and VAS. Table 3 provides a summary of the SF-MPQ
results ordered by the average severity score of the painTable 2 Symptoms associated with abdominal attacks1
Symptoms n2 % all attacks
(N = 296)
% attacks with any abdominal
symptoms (N= 154)
Distention 118 40% 77%
Cramping 112 38% 73%
Nausea 103 35% 67%
Vomiting 32 11% 21%
Diarrhea 21 7% 14%
Other symptoms3 62 21% n/a
1All patients with abdominal symptoms in EDEMA0, EDEMA1 and EDEMA2.
2Number of attacks with the symptom at baseline.
3Free-form text box included: pain, discomfort, tenderness, hyperactive bowel
sounds, increased bowl activity, constipation, urgency, peripheral swelling,
rash, redness, itching.descriptor (scale: 0 = none; 3 = severe). The dataset in-
cluded 502 attacks with any abdominal symptoms cap-
tured in EDEMA0, EDEMA1, EDEMA2 and DX-88/19.
The severity of the affective and sensory dimensions of
the McGill pain score at baseline and 4 hours post-dosing
with 30 mg SC ecallantide is presented in Figure 2A. Treat-
ment with ecallantide reduced the pain severity score
(median [SD]) at baseline to 4 hours post-dosing from
1.3 (0.8, 1.8) to 0.3 (0.0, 0.5) in the affective dimension
(N = 350 attacks) and from 1.4 (0.9, 1.8) to 0.3 (0.2, 0.5)
in the sensory dimension (N = 366 attacks). Similar to the
findings using the SF-MPQ, ecallantide also reduced me-
dian pain intensity as measured using the VAS (Figure 2B).White blood cell count and surgical history
White blood cell (WBC) count was measured in all HAE
attack patients. This dataset of primary abdominal at-
tacks included 183 patients with 569 primary abdominal
attacks; defined as moderate or severe abdominal symp-
toms in the absence of laryngeal symptoms. In 132 of
these attacks, WBC counts were elevated (mean ± SD:
15.1 ± 11.27 × 109/L; elevated = > 10 × 109/L). An elevated
WBC count was measured with 64% of severe abdominal
attacks compared to 34% of moderate attacks. In these 183
patients, 23% had previously received an appendectomy,
16.4% had received a cholecystectomy, 1.6% had received a
bowel resection, 2.7% had an exploratory laparotomy, and
8.2% had a hysterectomy.Characteristics of abdominal pain in pediatric patients
Abdominal symptoms in the pediatric subgroup of pa-
tients were evaluated to determine if children differed
from adults in their abdominal HAE attack presenta-
tion. For this pediatric subgroup, data from EDEMA0,
EDEMA1, EDEMA2 and DX-88/19 were analyzed. The
pediatric subgroup included 29 patients with 72 attacks
(age 9–17 years; 9 year old patient obtained a waiver for in-
clusion in the study). Forty of 72 (56%) attacks were classi-
fied as primary abdominal attacks and 28 of 72 (40%)
attacks were abdominal attacks only. As with adults, pri-
mary abdominal attacks were defined as moderate or
severe abdominal symptoms in the absence of laryngeal
symptoms. McGill data at baseline was collected for 50 at-
tacks in 19 pediatric patients with any abdominal symp-
toms. The top 5 descriptors of abdominal pain were tender
(1.92), cramping (1.64), aching (1.58), sickening (1.50) and
tiring-exhausting (1.44). VAS pain data was available from
15 pediatric patients treated for 39 attacks. At baseline, the
median (IQR) VAS pain score was 62 (50, 77) and 4 hours
post-ecallantide dosing this was reduced to a median score
of 11 (2, 25). The McGill descriptors and VAS pain scores
in pediatric patients are numerically similar to those re-
ported above for the overall population.
Figure 1 Additional symptom complexes associated with all attacks with any abdominal symptoms treated with subcutaneous ecallantide.
All patients treated with 30 mg SC ecallantide in EDEMA2, EDEMA3, EDEMA4, and DX-88/19. Ext. = external, H/N = head/neck, Int. = internal,
SC = subcutaneous. Percentages based on number of attacks.
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symptoms to SC ecallantide
Patient demographics
Table 4 provides summary data of patient demographics
and the number of attacks with any abdominal symp-
toms treated with 30 mg SC ecallantide in EDEMA2,Table 3 McGill Descriptor Severity Score (N = 502 attacks)1
















1All patients with abdominal symptoms in EDEMA0, EDEMA1, EDEMA2
and DX-88/19.
2Intensity scale: 0 = none, 3 = severe.EDEMA3, EDEMA4 and DX-88/19; N = 149 patients for
521 attacks. The overall population of SC treated patients
included 230 patients with 929 attacks and therefore 65%
(149/230) of patients presented with HAE attacks with
abdominal symptoms. The average number of attacks
with abdominal symptoms per patient was 3.5 (4.0 SD;
range 1–28).
Treatment outcome score
Figure 3 shows the mean change in Treatment Outcome
Score (TOS) at 1, 2, 3, 4 and 24 hours following SC ecal-
lantide for all HAE attacks with any abdominal symp-
toms. By 1 hour following SC ecallantide administration,
patients reached the minimally important difference
(MID = 30) for the TOS, which reflects a clinically mean-
ingful treatment response. As a comparison, MacGinnitie
et al. reported a TOS at 4 hours of 29 in placebo-treated
patients with abdominal symptoms [12].
Time to response
The time to beginning of improvement and the time to
significant improvement were collected in patients with
HAE attacks with any abdominal symptoms. The me-
dian time (95% CI) to beginning of improvement was
54 minutes (52, 55) following SC ecallantide administra-
tion versus 114 minutes in placebo treated patients. The
median time (95% CI) to significant symptom resolution
was 165 minutes (136, 167) for ecallantide treated attacks
versus > 4 hours (161, > 4 hours) for placebo.
AB
Figure 2 Changes in pain during an HAE attack at 4 hours post-dosing with 30 mg SC ecallantide. A) McGill Pain Score in both the
affective and sensory dimensions at baseline and 4 hours post-dosing with ecallantide. B) Visual Analog Scale pain intensity score at baseline and
4 hours post-dosing with ecallantide. Data from both analyses includes all patients treated with 30 mg SC ecallantide in EDEMA2 and DX-88/19
with any abdominal symptoms; analysis excludes attacks with missing data.
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The safety profile of ecallantide was similar to previous
reports, with potentially serious hypersensitivity repre-
senting the main safety concern. Anaphylaxis (based on
NIAID criteria [13]) occurred in 6 of the 149 patients
treated with SC ecallantide. All 6 reactions resolved fol-
lowing standard treatment (including epinephrine in 2
patients and no treatment in 2 patients). The most com-
mon treatment-emergent adverse events in all patients
with any abdominal symptoms treated with SC ecallan-
tide (N = 149) were: headache (14%), nausea (9%), fatigue
(8%) and HAE (7%).
Discussion
Diagnosis of HAE-C1INH in patients with recurrent ab-
dominal pain can be challenging, especially in the approxi-
mately 50% of cases that present only with abdominal
symptoms. These patients are very likely to be referred to
a Gastroenterologist at some point, particularly given thatabdominal symptoms occur in approximately 80% of pa-
tients [14] and on average it takes 10 years from the
time of onset of symptoms until a diagnosis is made [2].
It is commonplace for HAE-mediated abdominal pain
to be mistaken for other causes of abdominal pain, such
as appendicitis, cholecystitis and small bowel obstruction
[15,16]. As a consequence, many HAE patients report hav-
ing undergone unnecessary surgeries for their HAE symp-
toms including exploratory laparotomy, cholecystectomy
and hysterectomy [15,17]. We observed a similar surgical
history in patients enrolled in the clinical development
program for ecallantide. These results highlight the diffi-
culty in initially suspecting and then diagnosing HAE.
Once a diagnosis of HAE is suspected, there are several
published guidelines/consensus documents to aid the clin-
ician in the diagnosis and management of HAE patients
[18-21].
Historical data suggests that up to 80% of HAE patients
have recurrent abdominal pain [22]. This percentage is
Table 4 Patient demographics and number of abdominal
attacks in patients treated with 30 mg subcutaneous
ecallantide1
Patients (N = 149)
Patient demographics
Number of attacks 521









Number of abdominal attacks per patient
Mean (SD) 3.5 (4.0)
Range 1-28
Total Attacks, n (%)
1 attack 57 (38)
2 attacks 29 (19)
3 attacks 24 (16)
4 attacks 8 (5)
5 attacks 6 (4)
>5 attacks 25 (17)
1All patients treated with 30 mg subcutaneous ecallantide in EDEMA2,
EDEMA3, EDEMA4 and DX-88/19 with any abdominal symptoms.
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gram of ecallantide in which 65% (149/230) of patients
treated with SC ecallantide presented with HAE attacks
with abdominal symptoms. The most commonly reported
symptoms associated with abdominal attacks in this data-
set were distension (77%), cramping (73%) and nauseaFigure 3 Treatment Outcome Score (TOS) in all HAE attacks with any
patients treated with 30 mg SC ecallantide in EDEMA2, EDEMA3, EDEMA4,
with missing data.(67%), which is in agreement with previous reports [4,23].
These same symptoms were also commonly reported in
pediatric patients with HAE.
The percentage of HAE attacks with symptoms of
diarrhea (14%) and vomiting (21%) reported during the
ecallantide development program were lower than those
reported in previous studies. In two retrospective reports
from Bork and colleagues, the percentage of attacks with
vomiting were 83.3% and 73.3%, while 41.8% and 40.6%
of attacks had symptoms of diarrhea [4,23]. The reason
for the discrepancies between these studies is unclear
but may be due to differences in the severity of attacks
included in the analyses, as well as how the severity of
attacks was defined. Both reports from Bork et al. in-
cluded a high percentage of severe attacks, 78.7% and
70.0% respectively. In contrast, in the ecallantide devel-
opment program 37.9% of all attacks with abdominal
symptoms were rated as severe. It may be that diarrhea
occurs as the attack is resolving and the timing of the
data collection in the EDEMA program (within 8 hours
of symptom onset vs an average attack duration of 2 to
5 days) may not have detected this later symptom. In
addition, retrospective analyses are subject to recall bias
which may also contribute to the differences observed
between studies.
White blood cell (WBC) count is often used in the
differential diagnosis of acute abdominal pain and was
collected in patients with primary abdominal attacks in
the ecallantide development program. Interestingly, WBC
count was elevated in ~25% of attacks and was more likely
to be elevated in attacks rated as severe. This finding is in
agreement with several published case reports of abdominal
HAE attacks and therefore suggests that elevated WBC
count is not a reliable measure to include or exclude HAE
in the differential diagnosis of abdominal pain [24,25].
Indeed, Ohsawa et al. recently reported significant leuko-
cytosis with neutrophilia, as well as increased levels ofabdominal symptoms treated with SC ecallantide. Includes all
and DX-88/19 (N = 521 attacks in 149 patients); analysis excludes attacks
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tients with severe abdominal pain, when compared with
laboratory values when patients were not experiencing an
attack [26].
To date, there is no reliable marker to define abdominal
angioedema upon presentation of symptoms. Even in pa-
tients with a confirmed diagnosis of HAE, a diagnosis of
an abdominal attack depends upon clinical judgment and
the demonstrated efficacy of specific treatments. In un-
diagnosed patients, once HAE is suspected, blood tests
can be used to confirm the diagnosis but these results will
not be available for diagnosis and treatment in the initial
emergency setting. The initial screening test is C4 blood
levels, which will be low in HAE patients at baseline and
even lower during an acute attack. However, a reduced
C4 level during an attack does not identify the presence
or absence of angioedema. The C4 test is inexpensive,
common to most hospital laboratories, and typically has
a high sensitivity and specificity, with at least 95% of
HAE-C1INH patients showing a reduced C4 level dur-
ing remission and virtually 100% showing reduced C4
during an attack [27]. If the C4 is low, an abnormal
functional C1-INH test would confirm the diagnosis of
HAE [27]. The endoscopic and computerized tomography
(CT) appearance of abdominal angioedema has been pre-
viously reported and although nonspecific, in the right
clinical setting of association with skin swelling and a fam-
ily history, can suggest the diagnosis [16,24,25,28]. Typical
observations associated with abdominal angioedema in-
clude small bowel mucosal thickening, thumb printing of
the bowel wall and ascites [16,25].
There are now several therapeutic options available for
the treatment of HAE. These include both long-term
prophylaxis, as well as the treatment of acute attacks but
studies of comparative effectiveness among treatments
have not been conducted. Attenuated androgens have long
been used for HAE prophylaxis but can have serious side-
effects [29,30]. CINRYZE® (ViroPharma, Exton, PA) is a
nanofiltered, C1-INH (Human) replacement product also
approved for prophylaxis [31]. Acute treatment options
include: Berinert® (CSL Behring, Marburg, Germany), a
nanofiltered C1-INH (Human) replacement product [32];
FIRAZYR® (icatibant, Shire, Lexington, MA), a bradykinin
B2 receptor antagonist [33]; and KALBITOR® (ecallan-
tide, Dyax Corp., Burlington, MA), a plasma kallikrein
inhibitor [34].
Each of the HAE therapies have demonstrated efficacy
in the management and treatment of HAE but also carry
a risk of harm. As stated in the package inserts and re-
ported in the literature, the use of C1 Esterase Inhibitor
(Human) products is associated with serious arterial and
venous thromboembolic events [31,32,35]. The use of
icatibant is associated with injection site reactions, which
occurred in almost all patients (97%) in clinical trials [33].The major risk associated with use of ecallantide is hyper-
sensitivity reactions [34]. Anaphylaxis has been reported
after administration of ecallantide and because of this risk,
should only be administered by a healthcare professional
with appropriate medical support to manage anaphylaxis
and HAE [34]. In the study presented here, ecallantide
was shown to elicit a clinically meaningful treatment re-
sponse for abdominal attacks within 1 hour post dosing,
with significant symptom resolution occurring in 2 to
4 hours. Thus, in patients diagnosed with HAE-C1INH,
a variety of effective treatment options are available to
minimize the symptoms of HAE attacks and improve
overall quality of life.Conclusion
In summary, patients that present with attacks of recur-
rent abdominal pain that completely resolve in the ab-
sence of other symptoms are challenging to diagnose. The
data from this study provide information that should aid
the Gastroenterologist in suspecting the diagnosis of HAE
in patients with such unexplained bouts of severe abdom-
inal pain. Patients with HAE are likely to have intermittent
exacerbations of moderate to severe, poorly localized pain,
described as tender, tiring-or exhausting, aching cramping
or sickening. Elevation of white blood cells frequently
occurs during severe abdominal attacks and may lead to
exploratory laparotomy for concern of other more com-
mon conditions. As Gastroenterologists increase their
awareness of HAE, patients will be diagnosed earlier to
receive both timely and effective treatment.Additional file
Additional file 1: List of IRB/IECs in the clinical development
program for ecallantide.
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